Amarin Corp Plc (AMRN)

[HDGabor]

Total Revenue / 287,849
Cost of Revenue / 114,742
Gross Profit / 173,106

Research Development / 46,908
Selling General and Administrative / 92,164 (inc. 15,580 KOWA fee)
Total Operating Expenses / 139,072

Operating Income or Loss / 34,035

Notes 3,5% interest / 5,250
10% of NR to Biopharma / 28,785

License fee:

"Also under the Laxdale agreement, upon receipt of marketing approval in Europe for the first indication for Vascepa (or first indication of any product containing Amarin Neuroscience intellectual property acquired from Laxdale in 2004), we must make an aggregate stock or cash payment to the former shareholders of Laxdale (at the sole option of each of the sellers) of £7.5 million (approximately $12.8 million at June 30, 2014). Additionally, upon receipt of a marketing approval in the U.S. or Europe for a further indication of Vascepa (or further indication of any other product using Amarin Neuroscience intellectual property), we must make an aggregate stock or cash payment (at the sole option of each of the sellers) of £5 million (approximately $8.5 million at June 30, 2014) for each of the two potential market approvals (i.e. £10 million maximum, or approximately $17.0 million at June 30, 2014)."